As of 2024-12-13, the EV/EBITDA ratio of Revolution Medicines Inc (RVMD) is -11.89. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RVMD's latest enterprise value is 7,609.19 mil USD. RVMD's TTM EBITDA according to its financial statements is -639.94 mil USD. Dividing these 2 quantities gives us the above RVMD EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.7x - 17.4x | 16.0x |
| Forward P/E multiples | 15.7x - 21.4x | 15.8x |
| Fair Price | (58.68) - (64.92) | (59.29) |
| Upside | -226.4% - -239.8% | -227.7% |
| Date | EV/EBITDA |
| 2024-11-20 | -14.69 |
| 2024-11-19 | -14.53 |
| 2024-11-18 | -13.94 |
| 2024-11-15 | -14.18 |
| 2024-11-14 | -14.77 |
| 2024-11-13 | -14.97 |
| 2024-11-12 | -15.28 |
| 2024-11-11 | -15.62 |
| 2024-11-08 | -15.57 |
| 2024-11-07 | -15.22 |
| 2024-11-06 | -15.31 |
| 2024-11-05 | -14.60 |
| 2024-11-04 | -14.37 |
| 2024-11-01 | -14.17 |
| 2024-10-31 | -13.75 |
| 2024-10-30 | -12.96 |
| 2024-10-29 | -12.94 |
| 2024-10-28 | -12.24 |
| 2024-10-25 | -11.89 |
| 2024-10-24 | -12.11 |
| 2024-10-23 | -12.44 |
| 2024-10-22 | -12.07 |
| 2024-10-21 | -12.24 |
| 2024-10-18 | -12.94 |
| 2024-10-17 | -12.83 |
| 2024-10-16 | -12.94 |
| 2024-10-15 | -12.56 |
| 2024-10-14 | -12.62 |
| 2024-10-11 | -12.96 |
| 2024-10-10 | -12.70 |
| 2024-10-09 | -12.69 |
| 2024-10-08 | -12.77 |
| 2024-10-07 | -12.13 |
| 2024-10-04 | -12.12 |
| 2024-10-03 | -11.81 |
| 2024-10-02 | -11.77 |
| 2024-10-01 | -11.56 |
| 2024-09-30 | -11.61 |
| 2024-09-27 | -11.30 |
| 2024-09-26 | -11.21 |
| 2024-09-25 | -11.48 |
| 2024-09-24 | -11.36 |
| 2024-09-23 | -10.89 |
| 2024-09-20 | -11.62 |
| 2024-09-19 | -11.82 |
| 2024-09-18 | -11.27 |
| 2024-09-17 | -11.19 |
| 2024-09-16 | -11.39 |
| 2024-09-13 | -11.17 |
| 2024-09-12 | -10.72 |